GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (WBO:NVAX) » Definitions » NonCurrent Deferred Liabilities

Novavax (WBO:NVAX) NonCurrent Deferred Liabilities : €379 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Novavax NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Novavax's non-current deferred liabilities for the quarter that ended in Mar. 2025 was €379 Mil.

Novavax NonCurrent Deferred Liabilities Historical Data

The historical data trend for Novavax's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax NonCurrent Deferred Liabilities Chart

Novavax Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 152.69 169.37 570.57 426.71

Novavax Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 774.16 495.56 464.35 426.71 378.84

Novavax NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Novavax's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Novavax Business Description

Industry
Address
700 Quince Orchard Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.